1 Unpopular Stock That Deserves Some Love and 2 We Avoid
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. Keeping that in mind, here is one stock poised to prove Wall Street wrong and two where the outlook is warranted.
Two Stocks to Sell:
Paramount (PSKY)
Consensus Price Target: $9.81 (-3.7% implied return)
Owner of Spongebob Squarepants and formerly known as ViacomCBS, Paramount Global (NASDAQ:PSKY) is a major media conglomerate offering television, film production, and digital content across various global platforms.
Why Do We Pass on PSKY?
- Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 1.8% over the last five years was below our standards for the consumer discretionary sector
- Capital intensity will likely increase as its free cash flow margin is anticipated to drop by 1.8 percentage points over the next year
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Paramount’s stock price of $10.19 implies a valuation ratio of 12.5x forward P/E. To fully understand why you should be careful with PSKY, check out our full research report (it’s free).
Inspire Medical Systems (INSP)
Consensus Price Target: $60.40 (-3.3% implied return)
Offering an alternative for the millions who struggle with traditional CPAP machines, Inspire Medical Systems (NYSE:INSP) develops and sells an implantable neurostimulation device that treats obstructive sleep apnea by stimulating nerves to keep airways open during sleep.
Why Does INSP Fall Short?
- Revenue base of $898.7 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Projected sales decline of 3.5% for the next 12 months points to a tough demand environment ahead
At $62.45 per share, Inspire Medical Systems trades at 45.2x forward P/E. Check out our free in-depth research report to learn more about why INSP doesn’t pass our bar.
One Stock to Watch:
Molina Healthcare (MOH)
Consensus Price Target: $209.12 (2.8% implied return)
Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE:MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.
Why Do We Like MOH?
- Annual revenue growth of 13.7% over the last five years beat the sector average and underscores the unique value of its offerings
- Sizeable revenue base of $44.52 billion gives it economies of scale and favorable reimbursement terms with healthcare providers
Molina Healthcare is trading at $203.44 per share, or 28.1x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.